TRAIL agonists have shown anti-tumour effects in vitro and in vivo and have been tested as monotherapies in haematological malignancies, colorectal cancer and non-small cell lung cancer [50], with approximately 15% of patients treated with TRAIL agonists, having a long term response to TRAIL therapy. Here, TNFSF10 is linked to neoplasm.